Regulus Therapeutics Inc. – Consensus Indicates Potential -23.1% Downside

Broker Ratings

Regulus Therapeutics Inc. found using ticker (RGLS) now have 3 analysts in total covering the stock. The consensus rating is ‘Hold’. The range between the high target price and low target price is between 1.5 and 0.5 calculating the average target price we see 1. Now with the previous closing price of 1.3 this would imply there is a potential downside of -23.1%. The 50 day MA is 0.77 and the 200 day moving average is 0.69. The company has a market cap of $90m. Company Website: http://www.regulusrx.com

The potential market cap would be $69m based on the market concensus.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its two lead product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS4326, an anti-miR targeting miR-17, which is in Phase Ib clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products, which include RGLS5579 to inhibit miR-10b, and Hepatitis B virus program and Non-Alcoholic Steatohepatitis program. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index